Julia Marie Eastland insider trades: Zentalis Pharmaceuticals (ZNTL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Julia reports to the SEC
and 1 more company
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | ZNTL | ↓ Sell | 8,755 | $2.43 | $21K | Direct | Feb 10, 2026 (1d) |
| Jan 31, 2025 | ZNTL | ↑ Buy | 28,500 | $1.73 | $49K | Direct | Feb 4, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZNTL insiders
Open-market trades in the last 12 months
About Julia Marie Eastland's insider trades
Julia Marie Eastland is CEO & President at Zentalis Pharmaceuticals (ZNTL). Since Jan 31, 2025, Julia has reported 1 open-market purchase worth $49K and 1 sale worth $21K on SEC Form 4. In the last 12 months: 1 sale ($21K).
Their filings also include grants and awards (33 filings), shares returned to the company (3 filings), other transactions (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZNTL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.